keyword
MENU ▼
Read by QxMD icon Read
search

Breast endocrine surgery

keyword
https://www.readbyqxmd.com/read/28636294/-selective-therapeutic-de-escalation-in-early-stage-breast-cancer
#1
Aikaterini Liapi, Apostolos Sarivalasis, Wendy Jeanneret Sozzi, Loïc Lelièvre, Khalil Zaman
The survival of patients with breast cancer has improved considerably thanks to adjuvant radiotherapy and systemic treatments. Due to the potential adverse events associated with these treatments, a de-escalation effort was undertaken concerning surgery and more recently the adjuvant treatments. Conservative breast surgery and the avoidance of axillary dissection were possible for the majority of the patients without detrimental effect on survival. New radiotherapy techniques and the consideration of cancer biology allowed to better protect the peripheral organs and even to avoid treatment in certain low-risk patients...
May 17, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28592759/primary-breast-diffuse-large-b-cell-lymphoma-in-a-male
#2
Kiyonobu Tokuyama, Yasuaki Uemoto, Satoshi Kitagawa, Haruhiko Ohashi
A 74-year-old male with a mass in the right breast visited the Department of Breast and Endocrine Surgery in November 20XX. Core needle biopsy was performed. Pathological diagnosis was diffuse large B-cell lymphoma. The Ann Arbor clinical stage was IIA, and international prognostic index was low-intermediate. Six courses of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone and four courses of intrathecal chemotherapy were administered, and the patient achieved complete remission.
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28585885/validity-of-danish-breast-cancer-group-dbcg-registry-data-used-in-the-predictors-of-breast-cancer-recurrence-probecare-premenopausal-breast-cancer-cohort-study
#3
Deirdre P Cronin-Fenton, Anders Kjærsgaard, Thomas P Ahern, Marco Mele, Marianne Ewertz, Stephen Hamilton-Dutoit, Peer M Christiansen, Bent Ejlertsen, Henrik T Sørensen, Timothy L Lash, Rebecca A Silliman
BACKGROUND: Validation studies of the Danish Breast Cancer Group (DBCG) registry show good agreement with medical records for adjuvant treatment data, but inconsistent recurrence information. No studies have validated changes in menopausal status or endocrine therapy during follow-up. In a longitudinal study, we validated DBCG data using medical records as the gold standard. MATERIAL AND METHODS: From a cohort of 5959 premenopausal women diagnosed during 2002-2010 with stage I-III breast cancer, we selected 151 patients - 77 estrogen-receptor-positive and 74 estrogen-receptor-negative - from three hospitals...
June 6, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28585003/secondary-breast-carcinoma-after-completely-remitted-chronic-myeloid-leukemia-following-targeted-tyrosine-kinase-inhibitor-therapy
#4
Linlin Pan, Junwu Duan, Weiqiang Qiao, Lirong Bi, Di Wu, Zhimin Fan, Ming Yang
We describe a rare case of secondary breast carcinoma after chronic myeloid leukemia (CML) in a 56-year-old woman. The patient was treated with hydroxyurea and imatinib for CML and achieved complete remission (she has since been taking imatinib as the maintenance therapy). Four years later, the patient noticed a firm and painless lump in the left breast, which was diagnosed as ductal carcinoma in situ based on a percutaneous biopsy of the mass. Simple resection and sentinel lymph node biopsy of the left breast were then performed...
June 5, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28562530/adjuvant-endocrine-therapy-alone-in-patients-with-node-positive-luminal-a-type-breast-cancer
#5
Sungmin Park, Se Kyung Lee, Hyun-June Paik, Jai Min Ryu, Isaac Kim, Soo Youn Bae, Jonghan Yu, Seok Won Kim, Jeong Eon Lee, Seok Jin Nam
Luminal A breast cancer has a much better prognosis than other subtypes, with a low risk of local or regional recurrence. However, there is controversy around under- versus overtreatment with regard to adjuvant treatment of node-positive, luminal A breast cancer. The purpose of this study was to identify whether adjuvant systemic chemotherapy has any benefit in node-positive, luminal A breast cancer and to evaluate feasibility of endocrine therapy without chemotherapy in this group.This was a retrospective study of 11,025 patients who were surgically treated for invasive breast cancer at Samsung Medical Center between January 2004 and December 2013...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28526959/adjuvant-tamoxifen-but-not-aromatase-inhibitor-therapy-decreases-serum-levels-of-the-wnt-inhibitor-dickkopf-1-while-not-affecting-sclerostin-in-breast-cancer-patients
#6
Andy Göbel, Jan D Kuhlmann, Theresa Link, Pauline Wimberger, Andrew J Browne, Martina Rauner, Lorenz C Hofbauer, Tilman D Rachner
PURPOSE: Endocrine therapies, including tamoxifen or aromatase inhibitors, are indispensable for the treatment of patients with estrogen receptor (ER)- and/or progesterone-positive breast cancer. Whereas tamoxifen displays partial ER agonistic effects in bone, aromatase inhibitors increase bone resorption and fracture risk. The Wnt inhibitors dickkopf-1 (DKK-1) and sclerostin negatively impact bone formation and are considered targets for the treatment of bone disorders. However, the effect of endocrine therapies on serum DKK-1 and sclerostin levels in patients with primary breast cancer remains elusive...
May 19, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28516441/decision-making-in-the-surgical-management-of-invasive-breast-cancer-part-2-expanded-applications-for-breast-conserving-surgery
#7
REVIEW
Lisa A Newman
Treatment of early-stage invasive breast cancer with breast-conserving surgery plus radiation therapy (RT) yields overall survival outcomes equivalent to those achieved with mastectomy. Further, breast-conserving surgery is endorsed by the National Comprehensive Cancer Network as being supported by the highest-level, category 1 evidence. Advances in pathologic evaluation, management of multiple tumors, oncoplastic lumpectomy techniques, neoadjuvant chemotherapy, and hypofractionated RT can expand the pool of patients eligible for breast-conserving surgery...
May 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28511371/study-of-serum-total-psa-and-free-psa-as-an-oncological-marker-in-breast-tumour
#8
Elteza Tahjiba Jahir, Runi Devi, Bibhuti Bhushan Borthakur
INTRODUCTION: Breast Cancer (BC) cases are rising alarmingly all over the world and India is not an exception. This rising trend is due to an increased age at first child birth, decreased breast feeding, and the changing lifestyle mostly in urban India. With the advent of more sensitive methodologies and research works in this field, it has been suggested that Prostate Specific Antigen (PSA) plays an important role in the pathogenesis of breast cancer besides other established tumour markers...
March 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28509627/impact-of-risk-reducing-salpingo-oophorectomy-in-premenopausal-women
#9
R F M Vermeulen, M van Beurden, C M Korse, G G Kenter
OBJECTIVES: To describe implications of premenopausal risk-reducing salpingo-oophorectomy (RRSO) on quality of life, endocrine symptoms, sexual function, osteoporosis, cardiovascular health, metabolic syndrome, cognitive impairment and safety of hormone replacement therapy. METHODS: We searched the following electronic databases: The Cochrane Library, EMBASE, PsycInfo, and MEDLINE. We selected controlled and uncontrolled trials of premenopausal women undergoing RRSO...
June 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28491135/highlights-from-the-15th-st-gallen-international-breast-cancer-conference-15-18-march-2017-vienna-tailored-treatments-for-patients-with-early-breast-cancer
#10
Consuelo Morigi
The 15th St Gallen International Breast Cancer Conference was held in Vienna for the second time, from 15th-18th March 2017. 4000 people from 105 countries all over the world were invited to take part in the event. The real highlight of the conference was the last day with the International Consensus Session which was chaired by around 50 experts on breast cancer worldwide. With reference to data from scientific research, the consensus panel tried to offer guidelines for the management of breast cancer with the aim of providing patients with optimal treatment...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/28475932/therapeutic-escalation-de-escalation-data-from-15-508-early-breast-cancer-treated-with-upfront-surgery-and-sentinel-lymph-node-biopsy-slnb
#11
Gilles Houvenaeghel, Eric Lambaudie, Monique Cohen, Jean-Marc Classe, Fabien Reyal, Jean-Rémy Garbay, Sylvia Giard, Nicolas Chopin, Alejandra Martinez, Roman Rouzier, Emile Daraï, Pierre Emmanuel Colombo, Charles Coutant, Pierre Gimbergues, Pierre Azuar, Richard Villet, Christine Tunon de Lara, Emmanuel Barranger, Laura Sabiani, Anthony Goncalves
INTRODUCTION: The aim of this study was to examine changes in therapeutic practices for early breast cancer T0-2 N0 managed by upfront surgery and SLNB. POPULATION: Between 1999 and 2012, 15.508 patients were treated. Four periods were determined: 1999-2003, 2004-2006, 2007-2009 and > 2009. Five tumor subtypes were defined according to hormonal receptors (HR) and Her2: Luminal A (HR + Her2- Grade 1-2), Her2 (Her2+ HR-), Triple-negative (HR- Her2-), Luminal B Her2- (HR + Her2- Grade 3), Luminal B Her2+ (HR + HER2+)...
May 2, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28466123/the-role-of-quantitative-estrogen-receptor-status-in-predicting-tumor-response-at-surgery-in-breast-cancer-patients-treated-with-neoadjuvant-chemotherapy
#12
REVIEW
Jacques Raphael, Sonal Gandhi, Nim Li, Fang-I Lu, Maureen Trudeau
PURPOSE: Estrogen receptor (ER) negative (-) breast cancer (BC) patients have better tumor response rates than ER-positive (+) patients after neoadjuvant chemotherapy (NCT). We conducted a retrospective review using the institutional database "Biomatrix" to assess the value of quantitative ER status in predicting tumor response at surgery and to identify potential predictors of survival outcomes. METHODS: Univariate followed by multivariable regression analyses were conducted to assess the association between quantitative ER and tumor response assessed as tumor size reduction and pathologic complete response (pCR)...
May 2, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28408621/endocrine-therapy-initiation-and-medical-oncologist-utilization-among-women-diagnosed-with-ductal-carcinoma-in-situ
#13
Chelsea Anderson, Anne Marie Meyer, Stephanie B Wheeler, Lei Zhou, Katherine E Reeder-Hayes, Hazel B Nichols
BACKGROUND: Though randomized clinical trials have demonstrated a reduction in second breast events with endocrine therapy among women with ductal carcinoma in situ (DCIS), use of these therapies remains highly variable. The purpose of this study was to evaluate patient and treatment-related factors associated with endocrine therapy initiation and medical oncology specialty utilization after DCIS. MATERIALS AND METHODS: We identified women with a DCIS diagnosis during 2006-2010 in the North Carolina Central Cancer Registry with linked public and private insurance claims in the University of North Carolina Integrated Cancer Information Surveillance System data resource...
May 2017: Oncologist
https://www.readbyqxmd.com/read/28376176/tumor-sequencing-and-patient-derived-xenografts-in-the-neoadjuvant-treatment-of-breast-cancer
#14
Matthew P Goetz, Krishna R Kalari, Vera J Suman, Ann M Moyer, Jia Yu, Daniel W Visscher, Travis J Dockter, Peter T Vedell, Jason P Sinnwell, Xiaojia Tang, Kevin J Thompson, Sarah A McLaughlin, Alvaro Moreno-Aspitia, John A Copland, Donald W Northfelt, Richard J Gray, Katie Hunt, Amy Conners, Richard Weinshilboum, Liewei Wang, Judy C Boughey
Background: Breast cancer patients with residual disease after neoadjuvant chemotherapy (NAC) have increased recurrence risk. Molecular characterization, knowledge of NAC response, and simultaneous generation of patient-derived xenografts (PDXs) may accelerate drug development. However, the feasibility of this approach is unknown. Methods: We conducted a prospective study of 140 breast cancer patients treated with NAC and performed tumor and germline sequencing and generated patient-derived xenografts (PDXs) using core needle biopsies...
July 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28335784/the-benefit-of-adjuvant-radiotherapy-after-breast-conserving-surgery-in-older-patients-with-low-risk-breast-cancer-a-meta-analysis-of-randomized-trials
#15
Christiane Matuschek, Edwin Bölke, Jan Haussmann, Svjetlana Mohrmann, Carolin Nestle-Krämling, Peter Arne Gerber, Stefanie Corradini, Klaus Orth, Kai Kammers, Wilfried Budach
PURPOSE/OBJECTIVE(S): It is currently unclear whether patients with low risk breast cancer receiving adjuvant endocrine therapy need adjuvant radiation therapy after breast conserving surgery. The data of randomized trials are available. MATERIALS/METHODS: In a database search 5 randomized trials including in total 3766 mostly elderly patients with early stage breast cancer treated either with adjuvant endocrine therapy or with endocrine therapy and additional whole breast radiation after breast conserving surgery were identified...
March 23, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28332254/information-needs-and-decision-making-preferences-of-older-women-offered-a-choice-between-surgery-and-primary-endocrine-therapy-for-early-breast-cancer
#16
Maria Burton, Karen Kilner, Lynda Wyld, Kate Joanna Lifford, Frances Gordon, Annabel Allison, Malcolm Reed, Karen Anna Collins
OBJECTIVES: To establish older women's (≥75 years) information preferences regarding 2 breast cancer treatment options: surgery plus adjuvant endocrine therapy versus primary endocrine therapy. To quantify women's preferences for the mode of information presentation and decision-making (DM) style. METHODS: This was a UK multicentre survey of women, ≥75 years, who had been offered a choice between PET and surgery at diagnosis of breast cancer. A questionnaire was developed including 2 validated scales of decision regret and DM preferences...
March 23, 2017: Psycho-oncology
https://www.readbyqxmd.com/read/28327615/neoadjuvant-chemotherapy-creates-surgery-opportunities-for-inoperable-locally-advanced-breast-cancer
#17
Minghao Wang, Lingmi Hou, Maoshan Chen, Yan Zhou, Yueyang Liang, Shushu Wang, Jun Jiang, Yi Zhang
Neoadjuvant chemotherapy (NAC), the systematic chemotherapy given to patients with locally advanced and inoperable breast caner, has been proven to be of great clinical values. Many scientific reports confirmed NAC could effectively eliminate sub-clinical disseminated lesions of tumor, and improve long-term and disease-free survival rate of patients with locally advanced breast cancer (LABC); however, up to now, LABC is still a serious clinical issue given improved screening and early diagnosis. This study, with main focus on inoperable LABC, investigated the values of NAC in converting inoperable LABC into operable status and assessed the prognosis...
March 22, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28262606/adjuvant-therapy-in-patients-with-ductal-carcinoma-in-situ-of-the-breast-the-pandora-s-box
#18
REVIEW
Matteo Lazzeroni, Barbara K Dunn, Giancarlo Pruneri, Barbara Alicja Jereczek-Fossa, Roberto Orecchia, Bernardo Bonanni, Andrea DeCensi
Most patients with ductal carcinoma in situ of the breast (DCIS) are eligible for breast conservation treatment. The key management decision is whether to add radiotherapy and/or endocrine therapy to minimize the risk of a subsequent recurrence. Recent analyses indicating a lack of benefit in terms of breast cancer-associated mortality have suggested that more conservative approaches, omitting adjuvant therapy or even surgery, may be advisable in selected patients. These mortality observations are directly influenced by widespread use of mammographic screening which has opened a Pandora's box of subclinical DCIS and early invasive lesions...
April 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28247220/what-quality-of-life-issues-do-women-with-ductal-carcinoma-in-situ-dcis-consider-important-when-making-treatment-decisions
#19
Rebecca Mercieca-Bebber, Madeleine T King, Miriam M Boxer, Andrew Spillane, Zoë E Winters, Phyllis N Butow, Joan McPherson, Claudia Rutherford
PURPOSE: To explore quality-of-life (QOL) issues considered important when deciding on treatment for ductal carcinoma in situ (DCIS). METHODS: Breast Cancer Network of Australia members diagnosed with DCIS in the past 5 years (self-identified) participated in an online survey (Sep-Nov 2015). From a list of 74 QOL issues, participants selected all issues they experienced during DCIS diagnosis, treatment or recovery, then the issues they felt important to making a DCIS treatment decision, and completed the Health Literacy Questionnaire (HLQ)...
February 28, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28237423/what-influences-healthcare-professionals-treatment-preferences-for-older-women-with-operable-breast-cancer-an-application-of-the-discrete-choice-experiment
#20
J L Morgan, S J Walters, K Collins, T G Robinson, K-L Cheung, R Audisio, M W Reed, L Wyld
INTRODUCTION: Primary endocrine therapy (PET) is used variably in the UK as an alternative to surgery for older women with operable breast cancer. Guidelines state that only patients with "significant comorbidity" or "reduced life expectancy" should be treated this way and age should not be a factor. METHODS: A Discrete Choice Experiment (DCE) was used to determine the impact of key variables (patient age, comorbidity, cognition, functional status, cancer stage, cancer biology) on healthcare professionals' (HCP) treatment preferences for operable breast cancer among older women...
February 2, 2017: European Journal of Surgical Oncology
keyword
keyword
121072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"